Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Top Page
Intellia Therapeutics
(NASDAQ:NTLA)
Select Model
Select Model
Rating:56Neutral
Price Target:
$14.00
▲(9.29% Upside)
Action:ReiteratedDate:03/04/26
Overall score reflects weak fundamentals typical of a development-stage biotech (persistent losses and cash burn) as the primary constraint. Offsetting this are improving technicals and a moderately positive clinical/regulatory outlook (upcoming pivotal lonvo-z catalysts and MAGNITUDE restart), while valuation support is limited given negative earnings and no dividend.
Positive Factors
Pivotal Lonvo‑z Progress
Completing Phase 3 enrollment and targeting a mid‑2026 readout crystallizes a near‑term regulatory path for a potential first‑in‑class in vivo CRISPR therapy. A successful readout and BLA would transition Intellia toward product revenues, validate platform scalability and materially de‑risk the lead commercial program.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow reflect structural funding needs to advance clinical programs. Continued cash burn erodes runway, forces reliance on external financing or partnerships, and can dilute shareholders or constrain investments in manufacturing and commercialization at critical launch stages.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal Lonvo‑z Progress
Completing Phase 3 enrollment and targeting a mid‑2026 readout crystallizes a near‑term regulatory path for a potential first‑in‑class in vivo CRISPR therapy. A successful readout and BLA would transition Intellia toward product revenues, validate platform scalability and materially de‑risk the lead commercial program.
Read all positive factors
Intellia Therapeutics (NTLA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.55B
Dividend YieldN/A
Average Volume (3M)3.64M
Price to Earnings (P/E)―
Beta (1Y)2.14
Revenue Growth33.52%
EPS Growth21.66%
CountryUS
Employees403
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.83
Shares Outstanding118,133,545
10 Day Avg. Volume3,168,319
30 Day Avg. Volume3,640,283
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue21.44
Enterprise Value/Gross Profit-83.92
Enterprise Value/Ebitda-3.47
Forecast
1Y Price Target
$20.62Price Target Upside60.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)-3.62
Revenue Forecast (FY)$58.64M
Intellia Therapeutics Business Overview & Revenue Model
Company Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 f...
How the Company Makes Money
Intellia Therapeutics generates revenue through a combination of research collaborations, licensing agreements, and potential future product sales. The company often partners with larger pharmaceutical firms, which provide upfront payments and mil...
Intellia Therapeutics Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The call presents a mix of important clinical and commercial progress — most notably the completed Phase 3 enrollment and upcoming pivotal readout for lonvo-z, strong patient and physician interest, durable early efficacy signals, and improved near-term financial metrics — alongside meaningful risks: a still-pending FDA hold on the large cardiomyopathy ATTR program driven by serious liver enzyme events (including one patient death), material year-over-year cash depletion, and incomplete understanding of the safety signal’s mechanism and breadth. Management has secured a partial regulatory win (MAGNITUDE-2 hold lifted with specific mitigations) and emphasizes preparedness for a potential lonvo-z launch, but the unresolved MAGNITUDE hold and safety uncertainty inject non-trivial downside risk.Positive Updates
Lonvo-z Phase 3 Enrollment and Imminent Readout
Completed enrollment of the HAELO Phase 3 trial with 80 patients in ~9 months; top-line data expected by mid-2026 and a planned BLA submission in H2 2026 — positioning Intellia for the world’s first pivotal readout for an in vivo CRISPR gene-editing therapy.
Negative Updates
Clinical Hold on MAGNITUDE (Cardiomyopathy) Remains
MAGNITUDE (ATTR-CM) remains on clinical hold after elevated liver transaminases and total bilirubin observed in a patient; while the company is actively engaged with the FDA and has proposed mitigations, the hold has not yet been lifted, creating uncertainty for a large cardimyopathy cohort that had already enrolled >650 patients (vs ~550 expected).
Read all updates
Q4-2025 Updates
Positive
Negative
Lonvo-z Phase 3 Enrollment and Imminent Readout
Completed enrollment of the HAELO Phase 3 trial with 80 patients in ~9 months; top-line data expected by mid-2026 and a planned BLA submission in H2 2026 — positioning Intellia for the world’s first pivotal readout for an in vivo CRISPR gene-editing therapy.
Read all positive updates
Company Guidance
Management reiterated guidance for a big 2026 year: top‑line phase 3 lonvo‑z data by mid‑2026, a planned BLA submission in H2‑2026 and a potential launch in 2027; HAELO is fully enrolled (80 patients) and pooled data show 76% of patients ≥1 year post‑50 mg were attack‑free ≥12 months (versus ~20% attack‑free on current therapies), while market research (104 patients, 151 HCPs) showed 99% of patients would be at least somewhat likely to take lonvo‑z, 92% of HCPs could identify a patient, and physicians collectively manage ~4,000 patients (~60% of the U.S. treated population) and would prescribe to ~2,200 (54%). For ATTR, MAGNITUDE had >650 patients enrolled before the October hold, MAGNITUDE‑2 has 47 enrolled with a revised target of ~60 and is expected to complete enrollment in H2‑2026 after the FDA lifted the MAGNITUDE‑2 hold in late January; mitigation measures (extra LFT monitoring and short‑term steroid regimens) were agreed given a Grade‑4 LFT incidence of <1%. Financially, cash, cash equivalents and marketable securities were $605.1M at 12/31/25 (down from $861.7M a year earlier) with runway into H2‑2027, Q4 collaboration revenue was $23M, R&D was $88.7M (stock‑based comp $10.5M), G&A $33.1M (stock‑based comp $6.2M) and Q4 net loss was $95.8M (vs $128.9M prior year).Intellia Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 67.67M | 57.88M | 36.27M | 52.12M | 33.05M |
| Gross Profit | 51.75M | 47.59M | 27.30M | 44.55M | 26.16M |
| EBITDA | -396.77M | -523.98M | -506.31M | -450.59M | -260.96M |
| Net Income | -412.69M | -519.02M | -481.19M | -474.19M | -267.89M |
Balance Sheet | |||||
| Total Assets | 842.13M | 1.19B | 1.30B | 1.52B | 1.29B |
| Cash, Cash Equivalents and Short-Term Investments | 449.88M | 601.51M | 912.22M | 1.19B | 748.69M |
| Total Debt | 93.33M | 210.20M | 115.35M | 130.70M | 74.02M |
| Total Liabilities | 170.73M | 319.06M | 250.81M | 284.53M | 254.22M |
| Stockholders Equity | 671.39M | 871.96M | 1.05B | 1.24B | 1.04B |
Cash Flow | |||||
| Free Cash Flow | -354.66M | -354.66M | -408.07M | -391.68M | -237.79M |
| Operating Cash Flow | -348.88M | -348.88M | -394.09M | -333.29M | -225.03M |
| Investing Cash Flow | 125.57M | 125.57M | -31.35M | 160.31M | -550.78M |
| Financing Cash Flow | 185.75M | 185.75M | 130.32M | 582.96M | 736.69M |
Intellia Therapeutics Technical Analysis
Neutral
12.81
Price Trends
13.09
Negative
11.37
Positive
12.64
Positive
Market Momentum
0.03
Positive
47.38
Neutral
30.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Neutral. The current price of 12.81 is below the 20-day moving average (MA) of 13.44, below the 50-day MA of 13.09, and above the 200-day MA of 12.64, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 47.38 is Neutral, neither overbought nor oversold. The STOCH value of 30.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NTLA.
Intellia Therapeutics Risk Analysis
Intellia Therapeutics disclosed 1 risk factors in its most recent earnings report. Intellia Therapeutics reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Governance Q4, 2025
Intellia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.55B | -2.54 | -56.63% | ― | 33.52% | 21.66% | |
56 Neutral | $1.17B | -5.93 | -27.17% | ― | ― | -103.95% | |
52 Neutral | $734.90M | -3.27 | -102.59% | ― | ― | -5.18% | |
52 Neutral | $959.87M | -12.74 | -43.61% | ― | -100.00% | -28.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $845.56M | -7.53 | -11.55% | ― | -23.37% | -42.45% | |
49 Neutral | $1.00B | -6.98 | -14.16% | ― | 7.16% | 3.95% |
* Healthcare Sector Average
NTLA
Intellia Therapeutics
12.81
4.08
46.74%
KURA
Kura Oncology
8.07
0.95
13.34%
CMPX
Compass Therapeutics
5.33
3.17
146.76%
ABCL
AbCellera Biologics
3.31
0.78
30.83%
JANX
Janux Therapeutics Inc
13.56
-17.27
-56.02%
BCAX
Bicara Therapeutics Inc.
18.16
5.13
39.37%
Intellia Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Intellia Resumes Key Trial and Expands ATM Program
Positive
Mar 2, 2026
On March 2, 2026, Intellia Therapeutics, Inc. amended its at-the-market equity offering agreement with Jefferies LLC, raising the total program size from $750 million to about $1.04 billion and filing a new prospectus supplement to cover up to $40...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial
Neutral
Jan 27, 2026
On January 27, 2026, Intellia Therapeutics announced that the U.S. Food and Drug Administration lifted the clinical hold on its investigational new drug application for the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran in patients with heredit...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intellia Updates Investors on Nex-Z Trial Safety Hold
Negative
Jan 9, 2026
On January 9, 2026, Intellia Therapeutics updated its corporate presentation to investors, detailing the status of its CRISPR-based pipeline and providing additional disclosure on a serious safety event tied to its lead ATTR amyloidosis candidate,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.